Lipocine (LPCN) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$5.27

-0.17 (-3.13%)

(As of 04/19/2024 ET)

Source

Source	Headline
	Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com americanbankingnews.com - April 19 at 2:14 AM
	Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs msn.com - April 12 at 4:03 PM
	Lipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity finanznachrichten.de - April 11 at 1:14 PM
	Lipocine annonce les résultats positifs d'une étude sur le traitement de l'obésité fr.investing.com - April 11 at 1:14 PM
	Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity markets.businessinsider.com - April 11 at 8:14 AM
	Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity finance.yahoo.com - April 11 at 8:14 AM
	Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity prnewswire.com - April 11 at 7:00 AM
	StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) americanbankingnews.com - April 11 at 2:18 AM
	Lipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis finanznachrichten.de - March 28 at 2:58 PM
	Lipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study markets.businessinsider.com - March 28 at 9:58 AM
	Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis prnewswire.com - March 28 at 8:00 AM
	Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies \| DelveInsight finance.yahoo.com - March 25 at 11:28 PM
	Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 prnewswire.com - March 25 at 8:00 AM
	LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023 investorplace.com - March 7 at 5:03 PM
	Lipocine GAAP EPS of -$3.14 seekingalpha.com - March 7 at 1:21 PM
	Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 prnewswire.com - March 7 at 8:00 AM
	Lipocine to Present at 36th Annual Roth Conference finance.yahoo.com - March 6 at 4:36 PM
	Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 finance.yahoo.com - February 6 at 12:53 PM
	Lipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals finanznachrichten.de - February 2 at 2:06 PM
	Lipocine transfère la commercialisation de TLANDO à Verity Pharma fr.investing.com - February 2 at 9:05 AM
	Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals finance.yahoo.com - February 2 at 9:05 AM
	Lipocine Shares Rise Premarket on Tlando Licensing Deal marketwatch.com - January 18 at 12:44 PM
	Lipocine licenses Tlando testosterone therapy to Verity Pharma msn.com - January 18 at 12:44 PM
	Lipocine Signs TLANDO Franchise License Deal With Verity Pharma markets.businessinsider.com - January 18 at 12:44 PM
	Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada finance.yahoo.com - January 18 at 12:44 PM
	Lipocine to Present at Biotech Showcase 2024 finance.yahoo.com - December 19 at 12:29 PM
	Lipocine files for $150M mixed shelf msn.com - November 22 at 6:02 PM
	Lipocine to Share Cirrhosis Treatment LPCN 1148 Results at The Liver Meeting marketwatch.com - November 13 at 6:58 PM
	Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 finance.yahoo.com - November 13 at 6:58 PM
	Buy Rating for Lipocine: Anticipation of Successful LPCN 1154 Study and Strong Financial Position markets.businessinsider.com - November 10 at 9:37 AM
	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 finance.yahoo.com - November 8 at 12:59 PM
	Lipocine Inc LPCN morningstar.com - November 5 at 5:46 PM
	Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 finance.yahoo.com - November 1 at 8:52 AM
	Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression finance.yahoo.com - October 26 at 8:12 AM
	Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference finance.yahoo.com - October 23 at 7:29 PM
	Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference finance.yahoo.com - September 19 at 5:11 PM
	Looking for a Value Investment? Check out These 3 Pharma Stocks stocknews.com - August 17 at 3:01 PM
	LPCN: Trial Results Improve Outlook finance.yahoo.com - August 16 at 10:13 AM
	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 finance.yahoo.com - August 10 at 8:29 AM
	LPCN: 1148 Shows Muscle Loss Reversal finance.yahoo.com - July 31 at 6:25 PM
	Why Lipocine Stock Is Moving Higher Today? benzinga.com - July 27 at 1:35 PM
	Why Is Lipocine (LPCN) Stock Up 32% Today? investorplace.com - July 27 at 9:14 AM
	Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference finance.yahoo.com - June 14 at 12:35 PM
	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 finance.yahoo.com - June 7 at 8:57 AM
	Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression msn.com - May 16 at 2:41 PM
	Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression finance.yahoo.com - May 16 at 9:40 AM
	Recap: Lipocine Q1 Earnings msn.com - May 12 at 9:17 AM
	Lipocine: Q1 Earnings Snapshot apnews.com - May 11 at 8:00 AM
	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 finance.yahoo.com - May 11 at 8:00 AM
	First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 finance.yahoo.com - April 3 at 10:47 AM

Get Lipocine News Delivered to You Automatically

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

LPCN Media Mentions By Week

LPCN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LPCN
News Sentiment
▼
0.45

0.52
▲
Average
Medical
News Sentiment

LPCN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LPCN Articles
This Week
▼
2

1
▲
LPCN Articles
Average Week

Get Lipocine News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:LPCN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lipocine (LPCN) News Today

LPCN Media Mentions By Week

LPCN Media Sentiment

LPCN News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info